Platelet-derived growth factor-? receptor-positive oligodendroglia are frequent in multiple sclerosis lesions
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Platelet-derived growth factor (PDGF) ligand is a potent glial cell mitogen. When its cognate receptor (PDGF-alphaR) is expressed on oligodendroglial lineage cells, such cells are considered capable of division, and the receptor thus serves as a phenotypic marker for oligodendrocyte precursor cells. Here we identify using immunohistochemistry a considerably enlarged, PDGF-alphaR-expressing oligodendrocyte cell population within multiple sclerosis (MS) white matter lesions compared to control brains. Numerous PDGF-alphaR-positive oligodendroglia also colabel heavily with the nuclear cell proliferation marker antibody Ki-67. Our finding of large numbers of proliferating oligodendroglia in MS brains expressing up-regulated PDGF-alphaR suggests that these progenitor-like cells represent an important source of regenerating cells for the healing MS lesion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345
Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons
Barres, B. A., & Raff, M. C. (1993) · Nature · doi:10.1038/361258a0 · Cited by 673
Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐. (1993) · Annals of Neurology · doi:10.1002/ana.410330203 · Cited by 574
Wolswijk, G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-02-00601.1998 · Cited by 562
Oligodendrocytes in the early course of multiple sclerosis
Brück, W., Schmied, M., Suchanek, G., Brück, Y., Breitschopf, H., Poser, S., Piddlesden, S., & Lassmann, H. (1994) · Annals of Neurology · doi:10.1002/ana.410350111 · Cited by 216
Remyelination in multiple sclerosis
Lassmann, H., Brück, W., Lucchinetti, C., & Rodriguez, M. (1997) · Multiple Sclerosis Journal · doi:10.1177/135245859700300213 · Cited by 191
Cited by
Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion
Barnett, M. H., & Prineas, J. W. (2004) · Annals of Neurology · doi:10.1002/ana.20016 · Cited by 1,185
Why does remyelination fail in multiple sclerosis?
Franklin, R. J. M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn917 · Cited by 837
The therapeutic potential of neural stem cells
Martino, G., & Pluchino, S. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1908 · Cited by 744
Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation
Back, S. A., Tuohy, T. M. F., Chen, H., Wallingford, N., Craig, A., Struve, J., Luo, N. L., Banine, F., Liu, Y., Chang, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1279 · Cited by 612
Remyelination in multiple sclerosis
Piaton, G., Williams, A., Seilhean, D., & Lubetzki, C. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17530-1 · Cited by 441
Kirby, B. B., Takada, N., Latimer, A. J., Shin, J., Carney, T. J., Kelsh, R. N., & Appel, B. (2006) · Nature Neuroscience · doi:10.1038/nn1803 · Cited by 404
Pathology of multiple sclerosis and related inflammatory demyelinating diseases
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00002-9 · Cited by 303
Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord
Wolswijk, G. (2002) · Brain · doi:10.1093/brain/awf031 · Cited by 268
Stankoff, B., Aigrot, M.-S., Noël, F., Wattilliaux, A., Zalc, B., & Lubetzki, C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09221.2002 · Cited by 262
FTY720 modulates human oligodendrocyte progenitor process extension and survival
Miron, V. E., Jung, C. G., Kim, H. J., Kennedy, T. E., Soliven, B., & Antel, J. P. (2008) · Annals of Neurology · doi:10.1002/ana.21227 · Cited by 255
Lin, W., Kemper, A., Dupree, J. L., Harding, H. P., Ron, D., & Popko, B. (2006) · Brain · doi:10.1093/brain/awl044 · Cited by 222
Simpson, J. E., Fernando, M. S., Clark, L., Ince, P. G., Matthews, F., Forster, G., O'Brien, J. T., Barber, R., Kalaria, R. N., Brayne, C., et al. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00828.x · Cited by 215
A crucial role for Olig2 in white matter astrocyte development
Cai, J., Chen, Y., Cai, W.-H., Hurlock, E. C., Wu, H., Kernie, S. G., Parada, L. F., & Lu, Q. R. (2007) · Development · doi:10.1242/dev.02847 · Cited by 203
“Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies.”
InfluentialArmstrong, R. C., Le, T. Q., Frost, E. E., Borke, R. C., & Vana, A. C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-19-08574.2002 · Cited by 178
“…which regenerative responses can be optimized from the existing oligodendrocyte lineage cell populations that are now being identified in MS lesions (Scolding et al., 1998; Lucchinetti et al., 1999; Chang et al., 2000; Maeda et al., 2001; Solanky et al., 2001; Chang et al., 2002; Wolswijk, 2002).”
Stidworthy, M. F. (2004) · Brain · doi:10.1093/brain/awh217 · Cited by 158
“…lesions in multiple sclerosis patients contain oligodendrocyte progenitor cells (OPCs) (Scolding et al., 1998; Wolswijk, 1998; Chang et al., 2000; Maeda et al., 2001) or premyelinating oligodendrocytes (Chang et al., 2002), but remain chronically demyelinated without these cells differentiating…”
Murtie, J. C., Zhou, Y.-X., Le, T. Q., Vana, A. C., & Armstrong, R. C. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.12.006 · Cited by 157
Oligodendrocytes and the early multiple sclerosis lesion
Prineas, J. W., & Parratt, J. D. E. (2012) · Annals of Neurology · doi:10.1002/ana.23634 · Cited by 149
Statin Therapy Inhibits Remyelination in the Central Nervous System
Miron, V. E., Zehntner, S. P., Kuhlmann, T., Ludwin, S. K., Owens, T., Kennedy, T. E., Bedell, B. J., & Antel, J. P. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080947 · Cited by 141
Remyelinating strategies for the treatment of multiple sclerosis
Stangel, M., & Hartung, H.-P. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00105-3 · Cited by 126
Endogenous cell repair of chronic demyelination
Armstrong, R. C., Le, T. Q., Flint, N. C., Vana, A. C., & Zhou, Y.-X. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000205142.08716.7e · Cited by 125
Digestion products of the PH20 hyaluronidase inhibit remyelination
Preston, M., Gong, X., Su, W., Matsumoto, S. G., Banine, F., Winkler, C., Foster, S., Xing, R., Struve, J., Dean, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23788 · Cited by 107
Platelet-Derived Growth Factor Promotes Repair of Chronically Demyelinated White Matter
Vana, A. C., Flint, N. C., Harwood, N. E., Le, T. Q., Fruttiger, M., & Armstrong, R. C. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181587d46 · Cited by 101
“Immature oligodendrocyte lineage cells can persist in MS lesions (6, 7, 12, 47).”
Decreased Oligodendrocyte Nuclear Diameter in Alzheimer's Disease and Lewy Body Dementia
Gagyi, E., Kormos, B., Castellanos, K. J., Valyi‐Nagy, K., Korneff, D., LoPresti, P., Woltjer, R., & Valyi‐Nagy, T. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00595.x · Cited by 38
Remyelinating and neuroprotective treatments in multiple sclerosis
Stangel, M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.331 · Cited by 22
Metadata
- Authors
- Maeda, Y., Solanky, M., Menonna, J., Chapin, J., Li, W., & Dowling, P.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2001
- Volume
- 49
- Issue
- 6
- Pages
- 776-785
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2016035349
- Cited by
- 111
- References
- 7
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.